BMJ Open (Dec 2022)

Developing and testing unconditional cash transfer strategies among young adults with first-episode psychosis in South Africa: a study protocol for a pilot randomised control trial (PRS-FEP trial)

  • Richard Lessells,
  • Andrew Tomita,
  • Vuyokazi Ntlantsana,
  • Thirusha Naidu,
  • Bonginkosi Chiliza,
  • Saeeda Paruk,
  • Lise Jamieson,
  • Joyce Protas Mlay,
  • Busisiwe Siphumelele Bhengu,
  • Jonathan K Burns

DOI
https://doi.org/10.1136/bmjopen-2022-067026
Journal volume & issue
Vol. 12, no. 12

Abstract

Read online

Introduction Access to mental health services is a challenge, especially for young people who are over-represented in the unemployment and poverty index in South Africa. Therefore, continuing care is a problem after hospital discharge for young people with first-episode psychosis (FEP) due to a lack of clinical engagement and follow-up, for which they need support, including financial, to improve their outcomes. This pilot randomised control trial (RCT) aims to assess the feasibility and acceptability of financial support, in the form of an unconditional cash transfer (UCT), among young patients with FEP to prevent relapse.Methods and analysis This study will use a 1:1 ratio two-arm open-label pilot RCT of 60 young participants (18–29 years) with FEP in remission, who will be recruited from specialised psychiatric facilities in KwaZulu-Natal Province, South Africa. This study will implement an UCT and assess its feasibility, acceptability and preliminary clinical outcomes (ie, medication adherence, relapse, quality of life, personal and social function). The follow-up time will be 3 months, the outcomes being measured at baseline, months 1 and 3. Descriptive and conventional content analysis will be done for quantitative and qualitative data, respectively.Ethics and dissemination The study obtained provisional approval from the Biomedical Research Ethics Committee at the University of KwaZulu-Natal(#BREC/00004117/2022). Also is registered on the South African National clinical trial registry (#DOH-27-092022-5894) and approved by the KwaZulu-Natal department of health (#NHRD Ref: KZ_2002209_033). The results from this investigation will be actively disseminated through peer-reviewed journal publications, conference presentations and stakeholder engagement.Trial registration number DOH-27-092022-5894.